Skip to content
CompletedEarly Phase 1

Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing

NCT03019822 · LAM · University Hospital, Basel, Switzerland

Closed to entry
Status
Not accepting participants
Early Phase 1
Phase
28
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

The study will test the effect of dopamine, serotonin, and direct 5-HT2A receptor stimulation on empathy, mood perception, and amygdala activity to fearful stimuli. In addition, we predict associations between subjective effects/alterations in emotion processing tests and functional imaging (fMRI) activity.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Emotional enhancement as determined by fMRI

    Measured over 12 hours

  • fMRI brain activity

    Measured over 1 hour

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

25 Years to 50 Years
Ages
All
Sex
Accepted
Healthy volunteers
Inclusion Criteria: 1. Age between 25 and 50 years. 2. Sufficient understanding of the German language 3. Subjects understand the procedures and the risks associated with the study. 4. Participants must be willing to adhere to the protocol and sign the consent form. 5. Participants must be willing to refrain from taking illicit psychoactive substances during the study. 6. Participants must be willing to drink only alcohol-free liquids and no coffee, black or green tea, or energy drink after midnight of the evening before the study session, as well as during the study day. 7. Participants must be willing not to drive a traffic vehicle or to operate machines within 48 h after substance administration. 8. Women of childbearing potential must have a negative pregnancy test at the beginning of the study. Pregnancy tests are repeated before each study session. Women and men must agree to use an effective form of birth control (double-barrier method). 9. Body mass index 18-29 kg/m2. Exclusion Criteria: 1. Chronic or acute medical condition 2. Hypertension (\>140/90 mmHg) or Hypotension (SBP\<85 mmHg) 3. Current or previous major psychiatric disorder 4. Psychotic disorder in first-degree relatives 5. Illicit substance use (with the exception of cannabis) more than 10 times or any time within the previous two months. 6. Pregnant or nursing women. 7. Participation in another clinical trial (currently or within the last 30 days) 8. Use of medications that may interfere with the effects of the study medications (any psychiatric medications). 9. fMRI related criteria including: metal implants (clips from operations, cochlea, large red/yellow tattoos in the neck area) 10. Tobacco smoking (\>10 cigarettes/day) 11. Consumption of alcoholic drinks (\>10/week)

Where

1 study site

FacilityCityRegionCountry
University Hospital BaselBaselCanton of Basel-CitySwitzerland

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT03019822 on ClinicalTrials.gov →

Last updated in the registry 2018-10-15. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits